2-(2-乙氧基苯氧基)乙基胺 | 6781-17-5

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(2-乙氧基苯氧基)乙基胺
• 中文别名: 2-(2-乙氧基苯氧基)苯乙胺；2-(2-乙氧基苯氧基)乙胺；2-(2-乙氧基苯氧基)-乙胺
• 英文名称: 2-(2-ethoxyphenoxy)-ethylamine
• 英文别名: 2-(2-ethoxyphenoxy)ethanamine；2-(2-ethoxyphenoxy)ethylamine；2-ethoxyphenoxyethylamine；2-(o-ethoxyphenoxy)ethylamine；2-(2-ethoxyphenoxy)-1-ethanamine；2-(2-ethoxy phenoxy) ethylamine
• CAS: 6781-17-5
• 化学式: C₁₀H₁₅NO₂
• mdl: MFCD06657756
• 分子量: 181.235
• InChiKey: OOKCBENPEIHOJG-UHFFFAOYSA-N

物化性质

• 沸点：
  96-100 °C(Press: 0.6 Torr)
• 密度：
  1.040±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-(2-乙氧基苯氧基)乙基胺 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 生成 5-[2-(2-ethoxyphenoxy)ethylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
  参考文献：
  名称：

  Novel phenoxyalkylamine derivatives. V. Synthesis, .ALPHA.-blocking activity and quantitative structure-activity analysis of .ALPHA.-((phenoxyethylamino)propyl)-.ALPHA.-phenylacetonitrile derivatives.

  摘要：

  合成了α-[(苯氧乙基氨基)丙基]-α-苯基乙腈衍生物，这些衍生物在苯乙腈部分的苯环（A环）上、在四面体碳原子上，以及在苯氧部分的苯环（B环）上，具有不同的取代基，并表现出各种程度的α-阻断活性。采用物理化学取代基参数及回归技术，对活性的变化进行了定性和定量分析。A环上取代基的影响根据其疏水参数的抛物线函数进行合理化。至于四面体碳原子上的取代基，烷基基团被认为是高活性的理想选择。B环上取代基的影响表明，存在一个最佳的疏水条件，并且在邻位的烷氧取代基以及在间位和对位的较小取代基有利于高活性。针对A环和B环取代基变化的综合系列类似物的分析显示，在分子的运输过程中，整个分子的最佳疏水性存在，此外也考虑了上述不同位置特异的结构效应。

  DOI：

  10.1248/cpb.36.4121
• 作为产物：
  描述：

  2-(2-ethoxyphenoxy)acetamide 在 二乙二醇二甲醚 、 diborane(6) 作用下， 生成 2-(2-乙氧基苯氧基)乙基胺
  参考文献：
  名称：

  Discovery of a new series of 5-HT1A receptor agonists

  摘要：

  Starting from compounds previously identified as alpha(1)-adrenoceptor antagonists that were also found to bind to the 5-HT1A receptor, in an attempt to separate the two activities, a new series of 5-HT1A receptor agonists was identified and shown to have high potency and/or high selectivity. Of these, compound 13, which combines high selectivity (5-HT1A/alpha(1) = 151) and good agonist potency (pD(2) = 7.82; E-max = 76), was found to be the most interesting. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.030

文献信息

• [EN] METHOD FOR PREPARING 2-ALKOXYPHENOXYETHANAMINES FROM 2-ALKOXYPHENOXYETHYLACETAMIDES<br/>[FR] PROCEDE DE PREPARATION DE 2-ALKOXYPHENOXYETHANAMINES A PARTIR DE 2-ALKOXYPHENOXYETHYLACETAMIDES
  申请人：MCM PHARMA GMBH

  公开号：WO2003095416A1

  公开（公告）日：2003-11-20

  The present invention relates to a method for preparing 2-Alkoxyphenoxyethanamines and more particularly relates to the preparation of the new chemical entity 2-Alkoxyphenoxyethylacetamides, in particular as intermediates in said method. An industrial process for the synthesis of 2-Alkoxyphenoxyethanamines which is cheap and easy to perform, is a long felt need for those skilled in the art. The object of the present invention is therefore to provide a process for the industrial production of phenoxyethanamine which is cheap and easy to perform. This object is solved by the new chemical entity 2-Alkoxyphenoxyacetamide which is prepared by reacting an ortho substituted phenol with a 2-Alkyloxazoline. By hydrolysis of the acetamide with water in the presence of organic or mineral acids such as hydrochloric acid and/or sulfuric acid, the 2-Alkylphenoxyethanamine is obtained.

  本发明涉及一种制备2-烷氧基苯氧乙胺的方法，更具体地涉及制备新化学实体2-烷氧基苯氧乙基乙酰胺，特别是作为该方法中的中间体。对于那些熟练的工艺人员来说，一种便宜且易于执行的合成2-烷氧基苯氧乙胺的工业化过程一直是迫切需要的。因此，本发明的目的是提供一种便宜且易于执行的工业生产苯氧乙胺的方法。这一目的通过新的化学实体2-烷氧基苯氧乙酰胺的制备来实现，该化合物是通过将邻位取代酚与2-烷氧噁唑啉反应制备的。通过在有机或矿物酸（如盐酸和/或硫酸）存在下用水水解乙酰胺，可以得到2-烷氧基苯氧乙胺。
• [EN] ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS DE MODULATION DES RÉCEPTEURS ADRÉNERGIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017197324A1

  公开（公告）日：2017-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with a β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了调节肾上腺素受体的化合物及使用方法。还提供了治疗与肾上腺素受体相关疾病或症状的方法，包括向受试者施用治疗有效量的该化合物。本公开的方面包括一种调节细胞中炎症通路的方法，例如在细胞中产生TNF-alpha。该方法可以包括将细胞与β1选择性肾上腺素受体调节化合物接触，以在细胞中选择性激活cAMP通路而不是β-arrestin通路。还提供了包含该化合物的药物组合物和试剂盒。
• Process for the separation of R(-)-and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide
  申请人：Fernandez Blanco Cristina

  公开号：US20050004398A1

  公开（公告）日：2005-01-06

  The process for separating the R(−)- and S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene-sulfonamide enantiomers comprises (a) reacting a mixture of said enantiomers with an optically active organic acid to form diastereoisomeric salts with said enantiomers, where in said diastereoisomeric salts have different solubility and can be separated by crystallization; (b) separating the diastereoisomeric salt mixture enriched in the salt of one of the enantiomers; and (c) releasing said salts to obtain the R(−)or S(+) enantiomer. The R(−)-5-[2-[[2-(2-ethoxyphenoxy) ethyl]amino]propyl]-2-methoxybenzenesulfonamide enantiomer has α-adrenergic blocking activity and is useful as an antihypertensive agent suitable for the treatment of congestive heart failure and benign prostatic hypertrophy.

  将R(−)-和S(+)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene-sulfonamide对映异构体分离的过程包括：(a)将混合的对映异构体与旋光有机酸反应，形成与该对映异构体形成的对映异构盐，其中所述对映异构盐具有不同的溶解度，可以通过结晶分离；(b)分离富集了其中一种对映异构体盐的对映异构盐混合物；和(c)释放所述盐以获得R(−)或S(+)对映异构体。R(−)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide对映异构体具有α-肾上腺素受体阻滞活性，可用作适用于治疗充血性心力衰竭和良性前列腺增生的降压药物。
• Process for resolution of tamsulosin and compounds, compositons, and processes associated therewith
  申请人：——

  公开号：US20030109752A1

  公开（公告）日：2003-06-12

  Optically impure tamsulosin including racemic tamsulosin can be resolved into optically pure (R)- or (S)-tamsulosin by the use of diastereomeric sulfonate salts of tamsulosin in a fractional crystallization technique. Racemic tamsulosin free base is a useful starting material for the resolution process and a method of obtaining the same in solid form, including two crystalline polymorphic forms, is also provided.

  包括消旋盐酸坦洛新在内的光学不纯的坦洛新可以通过使用坦洛新的对映异构磺酸盐在分馏结晶技术中分离成光学纯的(R)-或(S)-坦洛新。消旋盐酸坦洛新游离碱是分离过程的有用起始物质，同时还提供了一种获得固体形式的方法，包括两种晶态多型形式。
• Aminoalcohols
  申请人：Sumitomo Chemical Company, Limited

  公开号：US04001312A1

  公开（公告）日：1977-01-04

  Novel 4-amino-1-butanol derivatives having excellent depressant activity on central nervous system. A preferred compound of the disclosure is 4-[2-(2-alkoxyphenoxy)ethylamino]-1-(4-fluorophenyl)-1-butanol and its pharmaceutically acceptable salts.

  具有出色的中枢神经系统抑制活性的新型4-氨基-1-丁醇衍生物。该公开的首选化合物是4-[2-(2-烷氧基苯氧基)乙基氨基]-1-(4-氟苯基)-1-丁醇及其药用可接受的盐。